PURPOSE: We investigated the in vitro and in vivo anti-multiple myeloma activity of monoclonal antibody (mAb) 1339, a high-affinity fully humanized anti-interleukin 6 mAb (immunoglobulin G1), alone and in combination with conventional and novel anti-multiple myeloma agents, as well as its effect on bone turnover. EXPERIMENTAL DESIGN: We examined the growth inhibitory effect of 1339 against multiple myeloma cell lines in the absence and in the presence of bone marrow stromal cells, alone or in combination with dexamethasone, bortezomib, perifosine, and Revlimid. Using the severe combined immunodeficient (SCID)-hu murine model of multiple myeloma, we also examined the effect of 1339 on multiple myeloma cell growth and multiple myeloma bone disease. RESULTS: mAb 1339 significantly inhibited growth of multiple myeloma cell in the presence of bone marrow stromal cell in vitro, associated with inhibition of phosphorylation of signal transducer and activator of transcription 3, extracellular signal-regulated kinase 1/2, and Akt. In addition, mAb 1339 enhanced cytotoxicity induced by dexamethasone, as well as bortezomib, lenalidomide, and perifosine, in a synergistic fashion. Importantly mAb 1339 significantly enhanced growth inhibitory effects of dexamethasone in vivo in SCID-hu mouse model of multiple myeloma. mAb 1339 treatment also resulted in inhibition of osteoclastogenesis in vitro and bone remodeling in SCID-hu model. CONCLUSIONS: Our data confirm in vitro and in vivo anti-multiple myeloma activity of, as well as inhibition of bone turnover by, fully humanized mAb 1339, as a single agent and in combination with conventional and novel agents, providing a rationale for its clinical evaluation in multiple myeloma.
PURPOSE: We investigated the in vitro and in vivo anti-multiple myeloma activity of monoclonal antibody (mAb) 1339, a high-affinity fully humanized anti-interleukin 6 mAb (immunoglobulin G1), alone and in combination with conventional and novel anti-multiple myeloma agents, as well as its effect on bone turnover. EXPERIMENTAL DESIGN: We examined the growth inhibitory effect of 1339 against multiple myeloma cell lines in the absence and in the presence of bone marrow stromal cells, alone or in combination with dexamethasone, bortezomib, perifosine, and Revlimid. Using the severe combined immunodeficient (SCID)-hu murine model of multiple myeloma, we also examined the effect of 1339 on multiple myeloma cell growth and multiple myeloma bone disease. RESULTS: mAb 1339 significantly inhibited growth of multiple myeloma cell in the presence of bone marrow stromal cell in vitro, associated with inhibition of phosphorylation of signal transducer and activator of transcription 3, extracellular signal-regulated kinase 1/2, and Akt. In addition, mAb 1339 enhanced cytotoxicity induced by dexamethasone, as well as bortezomib, lenalidomide, and perifosine, in a synergistic fashion. Importantly mAb 1339 significantly enhanced growth inhibitory effects of dexamethasone in vivo in SCID-hu mouse model of multiple myeloma. mAb 1339 treatment also resulted in inhibition of osteoclastogenesis in vitro and bone remodeling in SCID-hu model. CONCLUSIONS: Our data confirm in vitro and in vivo anti-multiple myeloma activity of, as well as inhibition of bone turnover by, fully humanized mAb 1339, as a single agent and in combination with conventional and novel agents, providing a rationale for its clinical evaluation in multiple myeloma.
Authors: J-F Rossi; N Fegueux; Z Y Lu; E Legouffe; C Exbrayat; M-C Bozonnat; R Navarro; E Lopez; P Quittet; J-P Daures; V Rouillé; T Kanouni; J Widjenes; B Klein Journal: Bone Marrow Transplant Date: 2005-11 Impact factor: 5.483
Authors: Pierfrancesco Tassone; Paola Neri; Daniel R Carrasco; Renate Burger; Victor S Goldmacher; Robert Fram; Vidit Munshi; Masood A Shammas; Laurence Catley; Gary S Jacob; Salvatore Venuta; Kenneth C Anderson; Nikhil C Munshi Journal: Blood Date: 2005-04-07 Impact factor: 22.113
Authors: D Chauhan; S Kharbanda; A Ogata; M Urashima; G Teoh; M Robertson; D W Kufe; K C Anderson Journal: Blood Date: 1997-01-01 Impact factor: 22.113
Authors: H C van Zaanen; H M Lokhorst; L A Aarden; H J Rensink; S O Warnaar; J van der Lelie; M H van Oers Journal: Br J Haematol Date: 1998-08 Impact factor: 6.998
Authors: Peter M Voorhees; Qing Chen; Deborah J Kuhn; George W Small; Sally A Hunsucker; John S Strader; Robert E Corringham; Mohamed H Zaki; Jeffrey A Nemeth; Robert Z Orlowski Journal: Clin Cancer Res Date: 2007-11-01 Impact factor: 12.531
Authors: Honor J Hugo; Stephanie Lebret; Eva Tomaskovic-Crook; Nuzhat Ahmed; Tony Blick; Donald F Newgreen; Erik W Thompson; M Leigh Ackland Journal: Cancer Microenviron Date: 2012-02-08
Authors: Peter M Voorhees; Robert F Manges; Pieter Sonneveld; Sundar Jagannath; George Somlo; Amrita Krishnan; Suzanne Lentzsch; Richard C Frank; Sonja Zweegman; Pierre W Wijermans; Robert Z Orlowski; Britte Kranenburg; Brett Hall; Tineke Casneuf; Xiang Qin; Helgi van de Velde; Hong Xie; Sheeba K Thomas Journal: Br J Haematol Date: 2013-02-25 Impact factor: 6.998
Authors: T R Rosean; V S Tompkins; A K Olivier; R Sompallae; L A Norian; H C Morse; T J Waldschmidt; S Janz Journal: Leukemia Date: 2014-09-03 Impact factor: 11.528
Authors: Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz Journal: Immunol Res Date: 2014-08 Impact factor: 2.829
Authors: Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone Journal: Clin Cancer Res Date: 2012-10-03 Impact factor: 12.531
Authors: Emanuela Leone; Eugenio Morelli; Maria T Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone Journal: Clin Cancer Res Date: 2013-02-27 Impact factor: 12.531